Prospective Multicentre Evaluation of FUJIFILM SILVAMP TB LAM Test
Key Findings
A clinical trial evaluated the diagnostic accuracy of the urine-based lipoarabinomannan assay FUJIFILM SILVAMP TB LAM (FujiLAM) for tuberculosis in people living with HIV across seven high-burden countries.
Overall, the FujiLAM demonstrated a sensitivity of 54.4% and specificity of 85.2% against the extended mycobacterial reference standard (eMRS). However, there was significant variability in performance across different testing sites and lots used in the study.
Practical Solutions
While the current variability limits the clinical utility of FujiLAM, the lipoarabinomannan biomarker still shows promise for tuberculosis diagnostics, highlighting the need for further refinement.
Value
This evaluation emphasizes the importance of ongoing research and development in point-of-care tuberculosis diagnostics, with the potential to improve patient care and outcomes.
AI-Driven Platform for Clinical Trials and Medical Practice
Benefits of DocSym
DocSym, our AI-driven platform, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians, extending the benefits of clinical trials into everyday medical practice.
Streamlining Healthcare Operations
Our mobile apps support scheduling, monitoring treatments, and telemedicine, offering a digital solution to manage patient care and streamline healthcare operations in today’s environment.
Enhancing Workflows with AI
By leveraging AI, clinics can improve workflows, patient outcomes, and reduce paper-based routines, ultimately enhancing the delivery of healthcare services.
Learn more about how our platform can support your clinic at aidevmd.com.
